Merck KGaA (DE:MRK)
XETRA:MRK
Want to see DE:MRK full AI Analyst Report?
Top Page
Merck KGaA
(XETRA:MRK)
Select Model
Select Model
Rating:70Outperform
Price Target:
€142.00
▲(19.83% Upside)
Action:Upgraded
Date:05/16/26
The score is driven primarily by solid financial quality (strong margins and moderate leverage) tempered by weaker recent revenue/return trends and only moderate cash conversion. Technicals are supportive with an established uptrend and positive momentum, while valuation is reasonable but not especially cheap and the dividend yield is modest.
Positive Factors
Durable high margins
Sustained high gross and operating margins provide structural resilience versus peers, enabling the company to generate consistent operating cash and absorb pricing or volume shocks. Over 2–6 months this supports reinvestment in R&D, warranty of product margins and funding for strategic initiatives.
Negative Factors
Weak near-term revenue momentum
Soft or declining top-line momentum erodes the company's ability to grow absolute profit even with strong margins. Persisting weak revenues can force tighter cost controls, reduce investment capacity and limit market-share expansion absent new product or market catalysts.
Read all positive and negative factors
Positive Factors
Negative Factors
Durable high margins
Sustained high gross and operating margins provide structural resilience versus peers, enabling the company to generate consistent operating cash and absorb pricing or volume shocks. Over 2–6 months this supports reinvestment in R&D, warranty of product margins and funding for strategic initiatives.
Read all positive factors
Merck KGaA (MRK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€56.50B
Dividend Yield1.82%
Average Volume (3M)321.00K
Price to Earnings (P/E)22.5
Beta (1Y)1.00
Revenue Growth-1.69%
EPS Growth-10.15%
CountryDE
Employees59,020
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.82
Shares Outstanding129,242,250
10 Day Avg. Volume344,164
30 Day Avg. Volume321,004
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€136.88Price Target Upside15.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)7.98
Revenue Forecast (FY)€21.04B
Merck KGaA Business Overview & Revenue Model
Company Description
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and p...
How the Company Makes Money
Merck KGaA makes money primarily by selling products and services across its three business sectors. In Life Science, revenue is generated from supplying consumables and tools used by academic, pharmaceutical, and industrial customers, including l...
Merck KGaA Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.96B | 21.10B | 21.16B | 20.99B | 22.23B | 19.69B |
| Gross Profit | 12.27B | 11.89B | 11.95B | 11.67B | 12.84B | 11.60B |
| EBITDA | 6.39B | 5.95B | 6.17B | 5.83B | 6.79B | 5.99B |
| Net Income | 2.53B | 2.61B | 2.78B | 2.82B | 3.33B | 3.06B |
Balance Sheet | ||||||
| Total Assets | 53.07B | 52.10B | 51.57B | 48.49B | 48.53B | 45.36B |
| Cash, Cash Equivalents and Short-Term Investments | 2.74B | 2.74B | 2.71B | 2.41B | 1.64B | 1.62B |
| Total Debt | 12.04B | 11.97B | 10.27B | 9.94B | 10.40B | 10.77B |
| Total Liabilities | 23.25B | 23.44B | 21.58B | 21.74B | 22.52B | 23.95B |
| Stockholders Equity | 29.74B | 28.59B | 29.91B | 26.68B | 25.93B | 21.34B |
Cash Flow | ||||||
| Free Cash Flow | 2.42B | 2.35B | 2.40B | 1.76B | 2.45B | 3.19B |
| Operating Cash Flow | 4.19B | 3.93B | 4.59B | 3.78B | 4.26B | 4.62B |
| Investing Cash Flow | -4.60B | -4.26B | -3.05B | -1.89B | -2.74B | -1.58B |
| Financing Cash Flow | 2.17B | 628.00M | -985.00M | -1.73B | -1.55B | -2.50B |
Merck KGaA Technical Analysis
Positive
118.50
Price Trends
112.98
Positive
117.15
Positive
114.42
Positive
Market Momentum
4.75
Negative
71.31
Negative
91.54
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MRK, the sentiment is Positive. The current price of 118.5 is below the 20-day moving average (MA) of 119.51, above the 50-day MA of 112.98, and above the 200-day MA of 114.42, indicating a bullish trend. The MACD of 4.75 indicates Negative momentum. The RSI at 71.31 is Negative, neither overbought nor oversold. The STOCH value of 91.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MRK.
Merck KGaA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €56.50B | 22.46 | 8.77% | 1.82% | -1.69% | -10.15% | |
68 Neutral | €2.43B | 18.20 | 21.44% | 2.34% | -1.36% | 39.24% | |
63 Neutral | €20.47B | 13.84 | 7.76% | 2.05% | 4.22% | 248.36% | |
61 Neutral | €38.92B | 18.73 | 11.59% | 2.13% | -0.33% | 0.15% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | €14.80B | 104.02 | 6.05% | 0.39% | 3.20% | 70.35% | |
46 Neutral | €907.68M | -4.84 | -24.55% | ― | -5.48% | 6.43% |
* General Sector Average
DE:MRK
Merck KGaA
130.85
17.62
15.56%
DE:EVT
Evotec
5.28
-1.67
-24.05%
DE:FRE
Fresenius SE & Co. KGaA
36.27
-5.74
-13.66%
DE:SRT
Sartorius
194.60
22.75
13.24%
DE:DMP
Dermapharm Holding SE
48.75
14.61
42.79%
DE:SHL
Siemens Healthineers AG
34.92
-10.57
-23.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.